Because of the increasing use of IFN-␣ in both induction and maintenance therapy for multiple myeloma (MM), its effect on growth and apoptosis of myeloma cells is important to consider. To investigate the role of IFN-␣ on the growth of myeloma cells, we have studied its effects on the response of interleukin 6 (IL-6)-dependent myeloma cell line (ANBL6) and IL-6-independent myeloma cell line (C2E3) in the presence of IL-6 and dexamethasone (Dex). We found that although IFN-␣ is a potent inhibitor of proliferation, it has only a minimal effect on induction of apoptosis. Moreover, we found IFN-␣ as well as IL-6 can significantly suppress dexamethasone-induced apoptosis. The suppression of apoptosis is concurrent with the induction of both AP-1 and STAT binding activity. We also found that IL-6 but not IFN-␣ up-regulates Bcl-X L expression. However, IL-6-mediated Bcl-X L expression is suppressed in the presence of Dex. Therefore, the expression of Bcl-X L does not account for the protection of Dex-induced apoptosis by IFN-␣ and IL-6. Taken together, our results suggest that IFN-␣ may counteract the beneficial effects of corticosteroids or perhaps other apoptosis inducing agents in the treatment of myeloma.
Introduction
Dexamethasone (Dex) and interferon-␣ (IFN-␣) are commonly used in myeloma therapy and have been shown to inhibit myeloma cell growth in vitro and in vivo. [1] [2] [3] [4] [5] However, the results of studies on the effect of IFN-␣ treatment remain controversial. Two of 16 published studies showed IFN-␣ treatment can significantly prolong remission and median survival; four studies showed IFN-␣ can prolong the patients' remission but not survival; and nine studies concluded that the administration of IFN-␣ to myeloma patients had no beneficial effect on either prolonging the remission phase or survival of MM patients (reviewed in Ref. 6) . Despite the conflicting results of these clinical trials, IFN-␣ has been shown to inhibit the proliferation of MM cell lines in vitro 1, 4, 7 but its effect on inducing apoptosis of myeloma has not been examined. Recently, IFN-␣ has been shown to protect B cell chronic leukemia cells and lymphoma cells from apoptosis induced by a number of stimuli. [8] [9] [10] Milner et al 8 also showed the prevention of apoptosis is independent of growth arrest. However, the mechanism by which IFN-␣ prevents cells from undergoing apoptosis is still unclear.
Glucocorticoids have been shown to improve response rate and prolong survival of myeloma patients. 6 Studies have also demonstrated dexamethasone (Dex), an artificial form of glucocorticoids, effectively induces apoptosis of myeloma cell lines in vitro. 5, 11, 12 Dexamethasone is known as a potent apoptosis inducing agent for lymphoid cells. 13 Its suppression of AP-1 activity through direct protein-protein interaction is associated with its ability to induce program cell death. [14] [15] [16] as interleukin 2 and 4 have been shown to induce AP-1 activity to modulate dexamethasone-induced apoptosis. 14, 16 Interleukin 6 (IL-6) has been well characterized as a growth factor for MM cells. [17] [18] [19] Recent studies have shown that IL-6 can protect MM cells from Dex-induced apoptosis. 17, [20] [21] [22] Activation of the Ras/AP-1 pathway through IL-6 stimulation may account for this antiapoptotic effect. 12 However, the effect of IL-6 on AP-1 DNA binding activity was not investigated in these studies. Interestingly, Fukada et al 23 showed the activation of STAT3 through interleukin 6 receptor, gp130, is required to protect pro-B cells from apoptosis and the ectopic expression of a dominant negative form of STAT3 can block this protection. Furthermore, the activation of STAT3 is also associated with the increasing expression of Bcl-2 in this study. Interestingly, ectopic expression of Bcl-2 and IL-6-mediated Bcl-X L expression has been shown to be associated with the protection of mouse myeloma cells from apoptosis following cytokine deprivation. 21 Because of the increasing use of IFN-␣ in the treatment of myeloma in combination with other therapeutic agents such as dexamethasone, its effects on growth and apoptosis of myeloma cells is important to consider. In this study, we provide evidence that like IL-6, IFN-␣ protects myeloma cells from Dex-induced apoptosis and induces both AP-1 and STAT binding activity.
Materials and methods

Cell culture
The interleukin 6 (IL-6)-dependent cell line, ANBL6, and the IL-6-independent cell line, C2E3 (MM.1) have been previously described. 24, 25 Both cell lines were maintained in RPMI 1640 supplemented with 10% fetal calf serum, 50 U/ml each of penicillin and streptomycin, 2 mm l-glutamine (BRL, Gaithersburg, MD, USA). ANBL6 was maintained in the presence of 0.1 ng/ml IL-6 (R&D Systems, Minneapolis, MN, USA). All cultures were incubated in the absence of IL-6 for 3 days to eliminate the IL-6 effect on the cells and were then centrifuged on Ficoll-Histopaque to eliminate dead cells before each experiment. 3 
H thymidine incorporation assay
The assay was performed as previously described. 26 Briefly, cells were diluted to 2 × 10 5 cells/ml and 200 l of each culture was seeded to 96-well plates in the presence of 1 m Dex (ESI Pharmaceuticals, Cherry Hill, NJ, USA), 100 U/ml IFN-␣ (Roche Laboratories, Nutley, NJ, USA), and 1 ng/ml IL-6 unless otherwise indicated. The 96-well plates were incubated for 2 days before the addition of 1 Ci 
Apoptosis assay
The assay was performed as previous described. 26 Briefly, cells were washed and diluted to 2 × 10 5 cells/ml with RPMI 1640 with or without 1 m Dex, 100 U/ml IFN-␣, or 1 ng/ml IL-6 unless otherwise indicated. Cells were harvested and pelleted at the indicated time point. The cell pellets were suspended with 0.5 ml of hypotonic lysis solution (50 g/ml propidium iodide (Sigma, St Louis, MO, USA) in 0.1% sodium citrate and 0.1% Triton X-100) and incubated at 4°C for at least 3 h in the dark. Nuclear staining was analyzed on FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA, USA).
Nuclear extract preparation
Nuclear extracts were prepared as previously described. 27 Briefly, cells were washed with cold PBS two times and lysed in 5 pellet volumes of buffer A (10 mm Hepes (pH 7.9), 1.5 mm MgCl 2 , 10 mm KCl, 0.5 mm dithiothreitol (DTT), 0.1% Nonidet P-40 (NP40) on ice for 2 min. The nuclei were pelleted at 9000 g for 30 s at 4°C. The pellets were resuspended with 2 pellet volumes of buffer B (20 mm Hepes (pH 7.9), 25% glycerol, 0.42 m NaCl, 1.5 mm MgCl 2 , 0.2 m EDTA, 0.5 mm phenylmethylsulfonyl fluoride (PMSF), 0.5 mm DTT) and rocked at 4°C for 30 min to lyse the nuclei, followed by centrifugation at 1200 g for 20 min. The nuclear extracts were stored at −70°C until further use. The protein concentration of nuclear extracts was determined by a Bradford assay with Protein Assay Dye Reagent (Bio-Rad, Hercules, CA, USA).
Electrophoretic mobility shift assay (EMSA)
Ten micrograms of nuclear extract were incubated with the DNA binding mixture (20 mm Hepes (pH 7.9), 0.1 mm EDTA, 1 mm DTT, 0.1 mm PMSF, 1.5% glycerol, 1 g poly (dIdC) (Sigma), 20 000 c.p.m. of 32 P-labeled double-strand probe at room temperature for 30 min. The binding reaction mixtures were then electrophoresed on 4.5% polyacrylamide gel containing 5% glycerol at 35 mA for 3 h. Specific competitive probes were added to ensure the specificity. The sequences (sense strand shown) of oligonucleotide used in this study were as follows: consense AP-1, 5Ј-CTA GAT CCT CTA GAA CTG ACT CAT CGG ATC TAC-3Ј; SIE, 5Ј-AGC TTC ATT TCC CGT AAT CCC TAA AGC T-3Ј; NF-B, 5Ј-ATC CCC CAG AGG GGG ATT TCC AAG-3Ј.
Immunoblot analysis
5 × 10 5 cells were pelleted and suspended in 50 l of lysis buffer containing 50 mm Tris-HCl, (pH 7.4), 1% Nonidet P-40 (NP-40), 0.25% sodium deoxycholate, 150 mm NaCl, 1 mm EDTA, 1 mm PMSF, 1 g/ml of each aprotinin, leupeptin, pepstatin, 1 mm NaF. The cells were then rocked at 4°C for 30 min to lyse cells, followed by centrifugation at 1200 g for 20 min. The lysates were analyzed by SDS/PAGE and subsequent immunoblotting with first and HRP-conjugated secondary antibody by using an enhanced chemiluminescence (ECL) detection system (Amersham). The rabbit anti-Bcl-X L antibody was a generous gift from Dr Craig Thompson, 28 the mouse anti-ERK2 antibody was purchased from Upstate Biotechnology (Lake Placid, NY, USA), the HRP-conjugated anti-rabbit and mouse antibody were purchased from Amersham.
Results
IFN-␣ and Dex suppress proliferation of ANBL6 and C2E3 in a dose-dependent manner
To determine the effects of IFN-␣ and Dex on the proliferation of ANBL6 and C2E3 cells, we performed a 
IFN-␣ can further suppress the proliferation of ANBL6 and C2E3 cell lines in the presence of Dex
Because IFN-␣ is commonly used in combination with steroids, we examined whether IFN-␣ can enhance the Dex effect on the proliferation of myeloma cells in vitro. We examined the effect of the combination of IFN-␣ and Dex on 3 H thymidine incorporation in ANBL6 and C2E3 (Figure 1c and d) . Consistent with results in Figure 1a and b, Dex alone can dramatically suppress the 3 H thymidine incorporation in both cell lines. The addition of IFN-␣ to IL-6 + Dex-treated cells further suppressed thymidine incorporation of both cell lines up to 50% (compared to IL-6 + Dex treatment, Figure 1c and 1d) . This indicates that the combination of IFN-␣ and Dex treatment provides an additive effect on suppression of myeloma cell proliferation and also suggests IFN-␣ and Dex suppress the proliferation of myeloma cells through at least two different pathways.
IFN-␣ protects myeloma cells from Dex-induced apoptosis
Previous studies have demonstrated that IFN-␣ can prevent apoptosis of B cell chronic leukemia cells and lymphoma cells. [8] [9] [10] Due to the common use of combination treatments with IFN-␣ and other agents in MM treatment, we examined what effect IFN-␣ had on Dex-induced apoptosis. ANBL6 and C2E3 myeloma cells were treated with Dex, IFN-␣, and IL-6 alone or in various combinations. We monitored the apoptosis of cells by detecting hypodiploid nuclei with PI staining of nuclei followed by flow cytometery in a 4 day time course (Figure 2a and b) . We have previously demonstrated that results from PI staining of nuclei is consistent with the results from DNA laddering by gel electrophoresis. 17 As expected, ANBL6 and C2E3 underwent rapid apoptosis with Dex treat- ment. Eighty-seven percent of ANBL6 cells and 66% of C2E3 cells had undergone apoptosis by day 4. Consistent with our previous studies, 12 IL-6 treatment completely prevented Dexinduced apoptosis by day 4 in the IL-6-dependent cell line, ANBL6 (Figure 2a ). In agreement with results in Figure 2a , IL-6 also protected the IL-6-independent cell line, C2E3 from apoptosis ( Figure 2b) .
In contrast to its powerful inhibitory effect on proliferation of both cell lines, treatment with IFN-␣ alone did not induce ANBL6 and C2E3 to undergo apoptosis by day 4 (Figure 2a  and b) . Significantly, we found treatment by IFN-␣ protected ANBL-6 and C2E3 from Dex-induced apoptosis: 47% vs 21% death on day 2 and 87% vs 44% on day 4 in ANBL6; 31% vs 8% death on day 2 and 66% vs 45% death on day 4 in C2E3. To further confirm the effect of IFN-␣ and Dex on the growth of the cells, we examined the total cell number of ANBL-6 treated with IL-6, IFN-␣, Dex or their combination for 4 days (Figure 2c ). Consistent with Figure 2a , we found Dex significantly reduced cell number and IL-6 or IFN-␣ prevented the loss of cells in the presence of Dex. We then incubated ANBL6 with different concentrations of IFN-␣ in the presence of Dex. As shown in Figure 2d , IFN-␣ can protect cells from apoptosis at as little as 10 U/ml, with 87% vs 69% death and it can protect up to 55% of Dex-induced apoptosis at 500 U/ml (87% vs 39%) in ANBL6. The protection is apparently not associated with G1 cell cycle arrest, since ANBL6 is arrested in G1/S phase in the absence of IL-6.
12
The prevention of dexamethasone-induced apoptosis by IFN-␣ is concurrent with the upregulation of AP-1 (activating protein-1) binding activity.
Dex and other stimuli such as retinoic acid and UV-induced apoptosis have been shown to correlate with the reduction of AP-1 binding activity in human leukemic, neuron and mouse fibroblast cells. 16, 29, 30 Studies have also demonstrated cytokines such as IL-2 and IL-4 prevented cell apoptosis by increasing AP-1 binding activity.
14 To determine whether AP-1 is involved in the protection of Dex-induced apoptosis, we performed a gel shift analysis to examine AP-1 binding activity in nuclear extracts of ANBL6 cells (Figure 3) . Consistent with previous studies, 14, 16 we found Dex treatment reduced the AP-1 binding activity in ANBL6 (compare lane 1 and lane 2, Figure 3) . This is not due to the unequal loading since we used the same amount of nuclear extract in each binding reaction and the NF-B gel shift showed equal binding activity in each lane (Figure 3a) . In contrast to Dex, both IL-6 and IFN-␣ enhanced AP-1 binding activity with a peak activity around 1 h. Significant AP-1 binding activity was retained even in the presence of Dex (see Figure 3b ). IL-6 appeared to offer greater protection from the inhibitory effect of Dex on AP-1 binding activity. Notably, the level of the AP-1 activity in IL-6 + Dex and IFN-␣ + Dex-treated cells correlated with the level of the protection from apoptosis in ANBL6 cells (see Figure 2a) . Our results suggest that IFN-␣ as well as IL-6 upregulates the AP-1 activity to modulate Dex-induced apoptosis in MM cells.
Protection from Dex-induced apoptosis is also associated with the induction of STAT1 and STAT3 activity
Fukada et al 23 showed the activation of STAT3 through the IL-6 signal transducer, gp130, can prevent pro-B cells from apoptosis and the dominant negative STAT3 can block this protection. We examined whether the STAT3 activation is also associated with the IL-6 and IFN-␣ protection from apoptosis. To examine the activity of STAT3, we performed gel shift analysis to determine if the activation of STAT3 is associated with the protection in the myeloma cells (Figure 4 ). Consistent with a previous study, 7 IFN-␣ and IL-6 activated three major complexes, STAT3 homodimer, STAT1/STAT3 heterodimer and STAT1 homodimer (Figure 4a ) to bind to sis-inducing element (SIE). The maximum activation was reached by 30 min (Figure 4a and b) . However, IFN-␣ preferentially induces STAT1/STAT1 homodimer and STAT1/STAT3 heterodimer DNA binding activity. This is consistent with previous studies that STAT1 activation is essential for cell growth suppression in response to IFN-␥ and IFN-␣. [31] [32] [33] This is also consistent with the result that IFN-␣ but not IL-6 suppressed the proliferation of myeloma cells. Notably, the activation level of STAT1 and STAT3 protein by IL-6 and IFN-␣ is not affected by Dex treatment (Figure 4a and b) .
Interleukin 6 but not IFN-␣ upregulates Bcl-X L expression: however, IL-6 mediated Bcl-X L expression is completely suppressed in the presence of dexamethasone
In a recent study, Schwarze et al 21 showed both ectopic expression of Bcl-2 and IL-6-mediated expression of Bcl-X L are associated with the antiapoptotic effect of IL-6 in mouse myeloma cells. Some studies also suggest IFN-␣-mediated expression of Bcl-2 is associated with the protection from apoptosis in B cell chronic leukemia cells. 10, 34 We therefore examined whether the expression of Bcl-2, Bcl-X L and their counter partner, Bax, 35 were associated with the antiapoptotic effect of IFN-␣ and IL-6. We found no associated of IFN-␣ and IL-6-mediated antiapoptotic effect with the expression of Bax, Bcl-2 or Bcl-2/Bax ratios (data not shown). However, we found IL-6 but not IFN-␣ induced Bcl-X L expression in human 
Discussion
IFN-␣ has a wide range of cellular effects including regulation of cell proliferation and differentiation in different cell types and is widely used as an antitumor agent. In combination with other agents, such as Dex, IFN-␣ is also commonly used in the treatment of multiple myeloma. 6 However, its clinical value in multiple myeloma remains debatable due to conflicting results from different clinical trials. To further elucidate the effect of IFN-␣ on the growth of myeloma cells, we have studied the effects of IFN-␣ on proliferation and apoptosis in two different myeloma cell lines which have different growth requirements and genetic background.
IFN-␣ has been shown to inhibit proliferation of myeloma cells and IL-6 receptor (gp80) downregulation has been associated with this growth inhibition.
1,4 However, Jelinek et al 7
Figure 4
EMSA of STAT binding after various treatments in ANBL6 as indicated. Cells were treated as indicated in Figure 3 . The presence of STAT binding activity was determined by incubating nuclear extract with have demonstrated that IFN-␣ treatment decreased expression of gp80 but did not result in proliferation inhibition in one myeloma cell line (KAS-6/1). We have demonstrated that IFN-␣ can significantly suppress the 3 H thymidine incorporation of ANBL-6 cell line (about three-fold decrease) in the absence of endogenous and exogenous IL-6 (data not shown). These results suggests that a mechanism of IFN-␣-mediated growth inhibition other than gp80 downregulation must exist.
Although in vitro studies have demonstrated that IFN-␣ can suppress the proliferation of myeloma cells, little attention has been focused on the effect of IFN-␣ with other agents on the proliferation of myeloma cells. In recent studies, IFN-␣ prevented B cell chronic lymphocytic leukemia (BCLL) cells from apoptosis in vitro. The upregulation or preservation of Bcl-2 expression has been shown to be a possible mechanism of the protection 35 although one study showed IFN-␣ did not increase Bcl-2 expression. 9 Moreover, Milner et al 8 also demonstrated that IFN-␣ can protect Burkitt's lymphoma lines from Ca 2+ ionophore ionomycin induced apoptosis. In a recent study Egle et al 36 reported that IFN-␣ can block Fasinduced apoptosis in autonomously growing lymphoblastoid
Figure 5
Immunoblotting analysis of Bcl-X L expression in ANBL6. Cell lysates were prepared from ANBL6 cultured in the presence of 1 m Dex, 100 U/ml IFN-␣, 1 ng/ml IL-6 alone or various combinations (as indicated) for 48 h. The expression of Bcl-X L and ERK2 was determined by immunoblotting (a). The ERK2 expression was used as a loading control. The relative expression level of Bcl-X L /ERK2 was determined by densitometry (b). and myeloma cell lines. Our results suggest that IFN-␣ may be able to shield MM cells from other therapeutic agents that normally induce apoptosis when used in combination treatment. In this report, we used Dex, an effective apoptotic inducing agent, in combination with IFN-␣ to study their combined effect on the growth of myeloma cells. There are two major results of this study. First, IFN-␣ and Dex efficiently reduced the proliferation of myeloma cells. Moreover, we demonstrated that IFN-␣ can enhance the Dex-mediated inhibitory effect on myeloma cell proliferation. Second, we found that IFN-␣ did not induce apoptosis of myeloma cells and moreover IFN-␣ as well as IL-6 can suppress Dexinduced apoptosis.
To further explore the mechanism of this protection, we examined AP-1 binding activity in these cells. Dex-induced apoptosis has been associated with the loss of AP-1 binding activity through the direct interaction between the glucocorticoid receptor and either c-Jun or c-Fos. 15, 16 Bcl-2 stable transfectants and interleukin 2 as well as interleukin 4 have been shown to protect leukemia cells from Dex-induced apoptosis by upregulating AP-1 binding activity in the cells.
14 Lichtenstein et al 20, 37 have also demonstrated that MM cells were protected against Dex-induced apoptosis by IL-6 and insulinlike growth factors. However, the underlying mechanism was not further studied. Our data demonstrate that IFN-␣ as well as IL-6 upregulate AP-1 binding activity in myeloma cells and the level of AP-1 binding activation is associated with the protection from apoptosis.
We also demonstrate that IFN-␣ and IL-6 both activate STAT1 and STAT3 binding activity in myeloma cells. STAT3 activation has been demonstrated as an essential signal for the survival in gp 130 signal transduction. 23 Moreover, the SIE element is known as one of the sis-acting elements of c-Fos 38 and can increase the expression of c-Fos. One plausible mechanism is that STAT proteins are activated upon the stimulation of IL-6 and IFN-␣. The activation of STAT proteins then increases the expression of c-Fos and therefore increases the AP-1 activity to counteract the Dex-induced downregulation of AP-1 activity.
The STAT3-mediated upregulation of Bcl-2 expression has also been associated with its antiapoptotic effect. 23 Bcl-2 families are linked to the death and survival of the cells. 21, 23, 39, 40 However, there are a few conflicting studies. Doxorubicin has been shown to induce apoptosis but it increases Bcl-2 expression in myeloma cells. 20 IL-6 treatment has been shown to reduce the expression of Bcl-2 in the same study. Sangfelt et al 41 reported that there was no change in Bcl-2 or Bax protein levels that could account for the apoptosis induced by IFN-␣ in three hematologic lines. Xu et al 37 also reported that insulin-like growth factor-induced protection against dexamethasone was not associated with any alteration in quantitative or qualitative expression of Bcl-2, Bax or Bcl-X proteins in MM cells. Our results also demonstrate that change of Bcl-2, Bax, and Bcl-X L expression level cannot account for IL-6 and IFN-␣-mediated protection against Dex-induced apoptosis. Recent studies have suggested the phosphorylation status of Bcl-2 and Bad may change the activity of Bcl-2 families and alter the life and death signal of cells. 42, 43 Although our study was restricted to myeloma cell lines, clinical efficacy shows some significant associations with our findings. IFN-␣ maintenance therapy appears to prolong the duration of response and delay progression of multiple myeloma but has little effect on survival. 6, 44 There is no clinical evidence to suggest that interferon suppression of myeloma persists more than transiently after the drug is discontinued. This is compatible with the finding that IFN-␣ is an effective inhibitor of myeloma cell proliferation. The lack of a convincing survival benefit of IFN-␣ may reflect its lack of induction of apoptosis and thereby its inability to induce further reduction of tumor burden in most patients once chemotherapy is discontinued. The combination of IFN-␣ with Dex is an active regimen, but lately the contribution of IFN-␣ to its activity has been questioned. 6, 45 The present study would suggest that the interferon might actually counteract the Dex effect. The use of IFN-␣ in treatment cycles alternating with chemotherapy during a 2-year induction phase may be associated with an increased incidence of complete remission. 46 This was not noted when IFN-␣ was given simultaneously with the combination of melphalan and prednisone. 6 Taken together, these observations support the hypothesis that IFN-␣ should be used sequentially and not simultaneously with corticosteroids and perhaps other drugs that induce apoptosis. Indeed, in a recent review of multiple clinical trials that used IFN-␣ Joshua et al 6 note that the best response occurred in trials that used alternating or sequential cycles of IFN-␣, and the poorest response occurred in trials in which IFN-␣ was used in combination induction therapies.
It is becoming increasingly evident that the signaling cascades and transcription factors that regulate cell growth and cell death are distinct and respond differently to therapeutic agents. From our study it suggests the combined effects of multi-drug regimens on both proliferation and apoptosis is important to consider.
